热门资讯> 正文
Essential Pharmaceuticals宣布未经审计的第二季度初步收入在7.2亿至7.3亿美元之间
2025-07-21 20:23
- Amneal Pharmaceuticals (NASDAQ:AMRX) announced on Monday unaudited preliminary Q2 revenue of $720 million to $730 million, versus consensus revenue estimates of $748.18M, an increase of approximately 3% versus the same period in 2024.
- Shares of AMRX jumped nearly 7% during pre-market trading.
- Income before income taxes of $45 million to $56 million, versus $20 million in the same period in 2024.
- Adjusted EBITDA of $180 million to $185 million, an increase of approximately 13% versus the same period in 2024, said the company.
- Gross leverage decreased to 3.8x as of June 30, 2025, compared to 4.1x as of December 31, 2024, and net leverage decreased to 3.7x as of June 30, 2025, compared to 3.9x as of December 31, 2024, due to higher profitability and continued debt reduction, it added.
- The company plans to report Q2 2025 financial results on August 5, 2025.
- Source: Press Release
More on Amneal Pharmaceuticals
- How are generic drugmakers reacting to Trump’s push for domestic production?
- Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space
- Seeking Alpha’s Quant Rating on Amneal Pharmaceuticals
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
